Treatment of Residual Refraction Errors 6 Months After Trifocal IOL Implantation With Relex-Smile
Launched by EYE HOSPITAL PRISTINA KOSOVO · Jan 13, 2021
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Residual refractive errors(myopia 50% and hyperopia 30%) are the main problems at patients after IOL Implantation.
The residual refraction (myopic and hyperopic) after IOL Implantation is difficult to treat surgically. In addition, there are not many suitable options to offer such patients presenting with this condition.
Two current common surgeries to treat residual hyperopic refraction are refractive lens exchange (RLE) and excimer laser ablation (LASIK or PRK).
Laser procedures: Photorefractive keratectomy (PRK); Laser assisted in situ keratomileusis (LASIK); Risks of LASIK include ab...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • residual hypermetropic, myopic refraction on pseudophakic patients
- • low visual acuity
- Exclusion Criteria:
- • active anterior segment pathologic features,
- • previous corneal or anterior segment surgery,
- • glaucoma,
- • retinal detachment
About Eye Hospital Pristina Kosovo
Eye Hospital Pristina, located in Kosovo, is a leading clinical research institution dedicated to advancing ophthalmic care through rigorous clinical trials. Committed to improving patient outcomes, the hospital specializes in innovative treatments and technologies in eye health. With a multidisciplinary team of experienced ophthalmologists and researchers, Eye Hospital Pristina actively participates in collaborative studies aimed at enhancing the understanding and management of various eye conditions. The institution prioritizes patient safety and ethical standards, ensuring the highest quality of care and adherence to international research protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pristina, , Kosovo
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials